- Home
- MHUA vs APM Comparison
MHUA vs APM Comparison
Compare MHUA & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- APM
- Stock Information
- Founded
- MHUA 1990
- APM 2010
- Country
- MHUA China
- APM United Kingdom
- Employees
- MHUA N/A
- APM N/A
- Industry
- MHUA Medical Specialities
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- APM Health Care
- Exchange
- MHUA Nasdaq
- APM Nasdaq
- Market Cap
- MHUA 9.6M
- APM 8.3M
- IPO Year
- MHUA 2022
- APM 2018
- Fundamental
- Price
- MHUA $0.36
- APM $1.10
- Analyst Decision
- MHUA
- APM
- Analyst Count
- MHUA 0
- APM 0
- Target Price
- MHUA N/A
- APM N/A
- AVG Volume (30 Days)
- MHUA 222.1K
- APM 159.9K
- Earning Date
- MHUA 09-20-2024
- APM 12-20-2024
- Dividend Yield
- MHUA N/A
- APM N/A
- EPS Growth
- MHUA 29.93
- APM N/A
- EPS
- MHUA 0.37
- APM 0.00
- Revenue
- MHUA $94,252,537.00
- APM N/A
- Revenue This Year
- MHUA N/A
- APM $157,729.10
- Revenue Next Year
- MHUA N/A
- APM N/A
- P/E Ratio
- MHUA $0.98
- APM $419.22
- Revenue Growth
- MHUA N/A
- APM N/A
- 52 Week Low
- MHUA $0.25
- APM $0.46
- 52 Week High
- MHUA $1.47
- APM $17.49
- Technical
- Relative Strength Index (RSI)
- MHUA 56.71
- APM 45.00
- Support Level
- MHUA $0.33
- APM $1.02
- Resistance Level
- MHUA $0.37
- APM $1.80
- Average True Range (ATR)
- MHUA 0.02
- APM 0.14
- MACD
- MHUA 0.01
- APM -0.02
- Stochastic Oscillator
- MHUA 83.17
- APM 9.63
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.